- Home
- ISPC vs ALZN Comparison
ISPC vs ALZN Comparison
Compare ISPC & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- ALZN
- Stock Information
- Founded
- ISPC 2009
- ALZN 2016
- Country
- ISPC United States
- ALZN United States
- Employees
- ISPC N/A
- ALZN N/A
- Industry
- ISPC Precision Instruments
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- ISPC Health Care
- ALZN Health Care
- Exchange
- ISPC Nasdaq
- ALZN Nasdaq
- Market Cap
- ISPC 3.1M
- ALZN 2.6M
- IPO Year
- ISPC 2021
- ALZN 2021
- Fundamental
- Price
- ISPC $0.94
- ALZN $2.93
- Analyst Decision
- ISPC
- ALZN Strong Buy
- Analyst Count
- ISPC 0
- ALZN 1
- Target Price
- ISPC N/A
- ALZN $180.00
- AVG Volume (30 Days)
- ISPC 51.4K
- ALZN 711.6K
- Earning Date
- ISPC 08-05-2025
- ALZN 07-29-2025
- Dividend Yield
- ISPC N/A
- ALZN N/A
- EPS Growth
- ISPC N/A
- ALZN N/A
- EPS
- ISPC N/A
- ALZN N/A
- Revenue
- ISPC $8,058,631.00
- ALZN N/A
- Revenue This Year
- ISPC $35.93
- ALZN $322.64
- Revenue Next Year
- ISPC N/A
- ALZN N/A
- P/E Ratio
- ISPC N/A
- ALZN N/A
- Revenue Growth
- ISPC N/A
- ALZN N/A
- 52 Week Low
- ISPC $0.86
- ALZN $2.75
- 52 Week High
- ISPC $11.80
- ALZN $135.54
- Technical
- Relative Strength Index (RSI)
- ISPC 37.62
- ALZN 36.96
- Support Level
- ISPC $0.86
- ALZN $2.75
- Resistance Level
- ISPC $0.97
- ALZN $3.07
- Average True Range (ATR)
- ISPC 0.06
- ALZN 0.19
- MACD
- ISPC -0.02
- ALZN 0.05
- Stochastic Oscillator
- ISPC 18.79
- ALZN 19.66
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.